We demonstrated down-expression of ESM1 could enhance the viability, abilities of migration and invasion, and aggressiveness of human prostate cancer cells in vitro and in vivo by modulating cell-cycle related proteins, by controlling the expression of MMP-9 and TIMP-1, and by enhancing the phenotypic changes to cell proliferation. The gene discussed is MMP9; the disease is prostate carcinoma.